Kent Lake Capital LLC Reduces Stake in Science 37 Holdings, Inc. (NASDAQ:SNCE)

Kent Lake Capital LLC lowered its holdings in Science 37 Holdings, Inc. (NASDAQ:SNCE) by 74.3% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 278,560 shares of the company’s stock after selling 805,911 shares during the quarter. Kent Lake Capital LLC owned about 4.67% of Science 37 worth $1,488,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in the business. Verition Fund Management LLC acquired a new stake in shares of Science 37 in the 2nd quarter valued at about $33,000. Citigroup Inc. acquired a new stake in shares of Science 37 in the 1st quarter valued at about $37,000. Two Sigma Investments LP boosted its position in shares of Science 37 by 56.0% in the 4th quarter. Two Sigma Investments LP now owns 98,773 shares of the company’s stock valued at $41,000 after purchasing an additional 35,460 shares during the period. Prudential Financial Inc. acquired a new stake in shares of Science 37 in the 2nd quarter valued at about $46,000. Finally, Cubist Systematic Strategies LLC boosted its position in shares of Science 37 by 32.6% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 25,590 shares of the company’s stock valued at $51,000 after purchasing an additional 6,290 shares during the period. Hedge funds and other institutional investors own 40.67% of the company’s stock.

Science 37 Stock Performance

Science 37 stock traded up $0.02 during mid-day trading on Friday, reaching $5.75. 49,100 shares of the company were exchanged, compared to its average volume of 43,227. Science 37 Holdings, Inc. has a twelve month low of $3.73 and a twelve month high of $12.96. The firm has a market cap of $34.33 million, a PE ratio of -0.27 and a beta of 0.55. The firm’s 50-day simple moving average is $5.72 and its two-hundred day simple moving average is $5.99.

Analyst Ratings Changes

A number of analysts recently issued reports on SNCE shares. Robert W. Baird reissued a “neutral” rating on shares of Science 37 in a research report on Tuesday, January 30th. Craig Hallum reaffirmed a “hold” rating on shares of Science 37 in a research report on Monday, January 29th.

Science 37 Profile

Science 37 Holdings, Inc engages in patient-centric clinical trial activities in North Carolina. Its platform enables modern and digital approaches to clinical research, including the patient and trial investigators, nurses, coordinators, and sponsors, standardize evidence generation, and harmonize data.